Hemogenyx Pharmaceuticals has opened its new custom-engineered research and development facility at the Mink Building in West Harlem’s Manhattanville Factory District, adjacent to Columbia University and City College. The company’s state-of-the-art research facility includes approximately 10,000 rentable square feet of purpose-built lab space including two clean rooms for cell therapy manufacturing. In addition to continuing and expanding its research, Hemogenyx Pharmaceuticals can now manufacture cells in-house, accelerating and simplifying the commercialization of its major cell therapy product candidates. The Company will use its clean rooms to produce its Hemo-Car-T cell therapy for the treatment of acute myeloid leukemia.
Hemogenyx Pharmaceuticals previously was located at the SUNY Downstate campus in Brooklyn.
“It is exciting each time a new tenant opens here. With Hemogenyx Pharmaceuticals beginning work in such a highly specialized lab that required two clean rooms, the Manhattanville Factory District continues to deliver on its masterplan of becoming New York’s premier life science ecosystem,” said Scott Metzner, principal of the Janus Property Company, the project’s developer. “We are not only expecting to announce additional similar lab tenancies over the summer but are also pleased with our non-lab lease-up including at our recently completed Malt House.”
The Mink Building, located on West 126th Street at Amsterdam Avenue, has been completely rebuilt by Janus while preserving and enhancing the building’s singular industrial charms. The building features expansive ceiling heights and flexible, technology-enabled office and lab settings. Upon completion, the Factory District will total over one million square feet of new mixed-use buildings that will be interconnected by a series of beautifully-landscaped greenways and courtyards designed by Terrainwork.
